Internationally renowned Mount Sinai scientist Dr. Jeff Wrana received The Queen Elizabeth II Diamond Jubilee Medal this month from Prime Minister Stephen Harper in honour of his innovative research efforts and discovery in cancer. The commemorative medal was created last year by the Governor General of Canada to mark the 60th anniversary of her Majesty Queen Elizabeth II and serves to honour significant contributions and achievements by Canadians.
“Jeff is recognized internationally as one of Canada’s leading and most exciting cancer researchers so it’s truly wonderful that he is receiving this honour for helping to reduce the burden of this disease,” says Dr. Jim Woodgett, Director of Research at Mount Sinai’s Samuel Lunenfeld Research Institute.
A Senior Investigator at Mount Sinai’s Samuel Lunenfeld Research Institute and Professor at the University of Toronto’s Department of Molecular Genetics, Dr. Wrana studies the molecular basis of metastatic cancer and seeks to understand the processes by which tumour cells spread. Having made significant discoveries related to colorectal and other cancers, he is currently focused on advancing research and care in breast cancer. Dr. Wrana holds a Canada Research Chair in Systems Biology and is the Mary Janigan Research Chair in Molecular Cancer Therapeutics.
Are you a science teacher or thinking of becoming one? Watch this video and learn 3 rules to spark imagination and learning, and get students excited about how the world works.
A study published in PLOS ONE finds that Droplet Digital PCR (ddPCR™) technology is suitable for routine analysis of genetically modified organisms (GMOs) in food, feed, and seeds.
More than 60 countries representing 40 percent of the world’s population require labeling of food and feed when GMOs reach certain thresholds. Screening for and quantifying GMOs is essential to the integrity of this labeling policy.
“Droplet Digital PCR could replace or be a good alternative to qPCR, the current benchmark in GMO quantification,” said Dr. Dany Morisset, the paper’s lead author and a researcher at Slovenia’s National Institute of Biology. Dr. Morisset, in collaboration with the EU Reference Laboratory for GM Food and Feed (EU-RL GMFF), also coordinates an international R&D project to standardize screening methods for detecting GMOs in food and feed.
The paper showed that Droplet Digital PCR (ddPCR™) technology is more accurate and reliable than real-time quantitative PCR (qPCR) for quantifying GMOs, especially at low levels. Study authors also found that the ddPCR method meets international food standards of applicability and practicality.
qPCR has Drawbacks for Detecting GMOs
The most common technique for quantifying the presence of GMOs is qPCR, thanks to its accuracy and precision. However, according to Dr. Morisset, qPCR has several drawbacks. It is often unreliable and inaccurate when quantifying very small numbers of DNA targets or when those targets are part of complex matrices such as foods or feed that contain inhibitory substances.
A 2010 research study found that chamber digital PCR (cdPCR) delivered accurate quantification at low target copy number without the need for a standard curve. The matrix also did not inhibit cdPCR because it is an end-point assay and therefore its data are less affected by amplification efficiency. However, Dr. Morisset says its high costs make cdPCR impractical for real-world use.
The ddPCR System Meets or Exceeds International Recommendations for Performance Parameters
Dr. Morisset learned about Droplet Digital PCR technology, which was developed as an alternative to cdPCR with its easy workflow, low cost, and high throughput. Commercialized as the QX100™ Droplet Digital PCR system the ddPCR system provides thousands more partitions than in cdPCR, resulting in greater precision and per-sample costs that are up to 150 times less.
The Slovenian researchers analyzed food and feed matrices containing different percentages of a well-characterized GMO transgene. They found the ddPCR system’s performance parameters (precision, accuracy, sensitivity, and dynamic range) complied with the guidelines of the EU-RL GMFF and were comparable or superior to those for qPCR. Compared with the conventional qPCR assay, the ddPCR assay offered better accuracy at low target concentrations and greater tolerance to inhibitors found in matrices such as wheat flour and feed.
ddPCR Technology is Practical for Everyday Lab Use
International food safety standards specify that new methods should be easy for labs to implement in terms of cost, time, and workflow.
In the authors’ hands, a ddPCR assay requires 190 minutes and a qPCR assay takes 160 minutes for the typical number of samples run in parallel in midsize GMO laboratories. However, due to the greater number of PCR reactions required per sample in the qPCR assay, the time and expense of the qPCR assay grows rapidly with increasing sample throughput. Droplet Digital PCR is also simpler to set up and involves less hands-on labor than qPCR.
Dr. Morisset’s findings reveal that ddPCR is a less expensive alternative to qPCR due to the lower number of reactions. Droplet Digital PCR capitalizes on its ability to duplex as opposed to qPCR’s traditional approach of performing separate assays for both control and transgene targets. The ddPCR assay also doesn’t require reactions for a standard curve or dilutions due to lower anticipated inhibition.
McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson’s disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The Neuro, and Dr. Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine, have discovered the three-dimensional structure of the protein Parkin. Mutations in Parkin cause a rare hereditary form of Parkinson’s disease and are likely to also be involved in more commonly occurring forms of Parkinson’s disease. The Parkin protein protects neurons from cell death due to an accumulation of defective mitochondria. Mitochondria are the batteries in cells, providing the power for cell functions. This new knowledge of Parkin’s structure has allowed the scientists to design mutations in Parkin that make it better at recognizing damaged mitochondria and therefore possibly provide better protection for nerve cells. The research will be published online May 9 in the leading journal Science.